Engineered MS2 Virus Capsids for Cellular Display of Peptide Antigens.

Area of Science:

• Biotechnology
• Immunology
• Vaccine Development

Background:

• Rapid vaccine development is crucial for responding to pandemics and pathogen resistance.
• Existing vaccine platforms may lack modularity and efficiency for diverse pathogens.

Purpose of the Study:

• To develop a modular and rapidly adaptable viral capsid-based vaccine platform.
• To utilize enzymatic oxidative coupling for efficient antigen conjugation.
• To evaluate the platform's ability to activate the adaptive immune system in vitro.

Main Methods:

• Employed tyrosinase-mediated oxidative coupling to conjugate peptide antigens to MS2 viral capsids.
• Installed cysteine residues inside MS2 capsids for antigen conjugation.
• Assessed vaccine constructs for MHC presentation and T-cell activation using DC2.4 cells and T-cell hybridomas.

Main Results:

• MS2-peptide constructs demonstrated stability in serum and activated DC2.4 cells.
• Successfully achieved MHC presentation of peptide antigens.
• Induced antigen-specific T-cell activation in vitro, demonstrating immune system activation.
• MS2 capsid mutants acted as adjuvants, enhancing immune response.

Conclusions:

• The developed viral capsid platform is a stable, modular, and efficient system for vaccine creation.
• This platform enables rapid interchangeability of peptide antigens for diverse disease targets.
• Potential applications include vaccines against resistant pathogens and cancer immunotherapy.